AstraZeneca Weight-Loss Pill Shows Promising Results in Clinical Trials
HealthNews Service — AstraZeneca’s new weight-loss pill has demonstrated encouraging results in early clinical trials, raising hopes for a new treatment option in the battle against obesity. The pharmaceutical giant announced that the oral medication led to significant weight reduction in participants over a 12-week period, with minimal side effects reported.
The trial involved over 500 participants with a body mass index (BMI) of 30 or higher, or 27 with at least one weight-related comorbidity. Patients received either the drug or a placebo. Those on the active treatment lost an average of 8.5% of their body weight, compared to 2.3% in the placebo group. The drug works by mimicking a hormone that signals fullness, reducing appetite and food intake.
Dr. Sarah Mitchell, lead researcher on the study, stated, "These results are very promising. The pill offers a convenient, non-invasive option for patients who struggle with weight management. We are excited about the potential impact on public health." The most common side effects were mild nausea and diarrhea, which resolved over time.
AstraZeneca plans to move forward with larger Phase 3 trials to confirm efficacy and safety. If successful, the pill could become a key player in the weight-loss market, which is projected to reach $100 billion by 2030. The company expects to seek regulatory approval within two years.
Obesity affects over 650 million adults worldwide and is linked to numerous health conditions, including diabetes, heart disease, and certain cancers. Current treatments include lifestyle changes, surgery, and injectable medications like semaglutide. An oral option could improve accessibility and adherence.
Dr. James Carter, an obesity specialist at the University of Toronto, commented, "An effective oral medication would be a game-changer. Many patients are reluctant to use injections, so a pill could help more people achieve and maintain a healthy weight." However, he cautioned that long-term data are still needed.
AstraZeneca’s stock rose 3% following the announcement. The company is also exploring the drug’s potential for treating type 2 diabetes. The trial results were presented at the American Diabetes Association’s annual meeting.
